Organ procurement and transplantation network/united network for organ sharing histocompatibility committee collaborative study to evaluate prediction of crossmatch results in highly sensitized patients

Transplantation

Volumn 87, Issue 4, 2009, Pages 557-562

  Nikaein, Afzal ^a,b,r   Cherikh, Wida ^c   Nelson, Karen ^a,d   Baker, Timothy ^c   Leffell, Sue ^a,e   Bow, Laurine ^f   Crowe, Debbie ^g   Connick, Ketra ^h   Head, Mary Ann ⁱ   Kamoun, Malek ^j   Kimball, Pam ^k   Klohe, Ellen ^l   Noreen, Harriet ^a,m   Rebellato, Lorita ⁿ   Sell, Tom ^o   Sullivan, Karen ^p   Land, Geoffrey ^a,q  

^a UNITED NETWORK FOR ORGAN SHARING   (United States)

^b Texas Medical Specialty Inc   (United States)

^c VCU Office of Research   (United States)

^d PUGET SOUND BLOOD CENTER   (United States)

^e JOHNS HOPKINS HOSPITAL   (United States)

^f Hartford Transplant Center   (United States)

^g DCI Laboratory   (United States)

^h UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

ⁱ OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^j UNIVERSITY OF PENNSYLVANIA   (United States)

^k VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^l Inland Northwest Blood Center   (United States)

^m UNIVERSITY OF MINNESOTA   (United States)

ⁿ EAST CAROLINA UNIVERSITY   (United States)

^o Meritcare Health System   (United States)

^p TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^q HOUSTON METHODIST HOSPITAL   (United States)

^r Building C   (United States)

more..

Author keywords

HLA antibody identification; Prediction of crossmatch; Solid phase immunoassays

Indexed keywords

HLA ANTIGEN; PANEL REACTIVE ANTIBODY; ALLOANTIBODY;

ANTIBODY DETECTION; ARTICLE; B LYMPHOCYTE; CLINICAL EVALUATION; FLOW CYTOMETRY; HISTOCOMPATIBILITY; HUMAN; IMMUNOASSAY; KIDNEY DONOR; MAJOR CLINICAL STUDY; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; SENSITIZATION; T LYMPHOCYTE; BLOOD; DONOR; ENZYME LINKED IMMUNOSORBENT ASSAY; HISTOCOMPATIBILITY TEST; IMMUNOLOGY; METHODOLOGY; PREDICTION AND FORECASTING; STATISTICS; TRANSPLANTATION;

B-LYMPHOCYTES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HISTOCOMPATIBILITY; HISTOCOMPATIBILITY TESTING; HLA ANTIGENS; HUMANS; ISOANTIBODIES; PREDICTIVE VALUE OF TESTS; T-LYMPHOCYTES; TISSUE AND ORGAN PROCUREMENT; TISSUE DONORS;

EID: 65649146418     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181943c76     Document Type: Article

References (25)

1. Bray RA, Nolen JD, Larsen C, et al. Transplanting the highly sensitized patients: The Emory algorithm. Am J Transpl 2006; 6: 2307.
2. Vaidya S, Partlow D, Susskind B, et al. Prediction of crossmatch outcome of highly sensitized patients by single and/or multiple antigen beads luminex assay. Transplantation 2006; 82: 1524.
3. Halloran PF, Wadgymar A, Ritchie S, et al. The significance of the anti-class I antibody response. I. Clinical and pathologic features of anti-class I-mediated rejection. Transplantation 1990; 49: 85.
4. Monteiro F, Buelow R, Mineiro C, et al. Identification of patients at high risk of graft loss by pre-and post-transplant monitoring of anti-HLA class I IgG antibodies by enzyme-linked immunosorbent assay. Transplantation 1997; 63: 542.
5. Claas FHJ, Witvliet MD, Duquesnoy RJ,et al. The acceptable mismatch program as fast tool for highly sensitized patients awaiting a cadaveric kidney transplantation: Short waiting time and excellent graft outcome. Transplantation 2004; 78: 190.
6. Smits JMA, Van Houwelingen HC, De Meester J, et al. Analysis of the renal transplantation waiting list: Application of a parametric competing risk method. Transplantation 1998; 66: 1146.
7. Laux G, Mytilineos J, Opelz G. Critical evaluation of the amino acid triplet-epitope matching concept in cadaver kidney transplantation. Transplantation 2004; 77: 801.
8. Doxiadis II, Duquesnoy RJ, Claas FHJ. Extending options for highly sensitized patients to receive a suitable kidney graft. Current Option in Immunol 2005; 17: 536.
9. Duquesnoy RJ, Takemoto S, de Lange P, et al. HLA matchmaker; A molecularly based algorithm for histocompatibility determination-III. Effect of matching at the HLA-A, B amino acid triplet level on kidney transplant survival. Transplantation 2003; 75: 884.
10. Zachary AA, Delaney NL, Lucas DP, et al. Characterization of HLA class I specific antibodies by ELISA using solubilized antigen targets. I. Evaluation of the GTI QuickID assay analysis of antibody patterns. Hum Immunol 2001; 62: 228.
11. Kao KJ, Scornik JC, Small SJ. Enzyme-linked immunoassay for anti-HLA antibodies: Analternative to panel studiesby lymphocytotoxicity. Transplantation 1993; 55: 192.
12. Laundy GL, Bradley BA. The predictive value of epitope analysis in highly sensitized patients awaiting renal. Transplantation 1995; 59: 1207.
13. KermanR,Orosz C,LorberM.Clinical relevanceof anti-HLA antibodies pre and post transplant. Am J Med Science 1997; 313: 275.
14. Opelz, G. Non-HLA transplantation immunity revealed by lymphocytotoxic antibodies. Lancet 2005; 365: 1570.
15. Zachary AA, Montgomery RA, Jordan SC, et al. Antibodies in transplantation: Destroying old dogma, creating new paradigms. Tissue Antigens (in press) (Report from 14th IHIWS).
16. Jindra PT, Zhang X, Mulder A, et al. Anti-HLA antibodies can induce endothelial cell survival or proliferation depending on their concentration. Transplantation 2006; 82: S33.
17. Pollinger HS, Stegall MD, Gloor JM, et al. Kidney transplantation in patients with antibodies against donor HLA class II. Am J Transplantation 2007; 7: 857.
18. Bielman D, Honger G, Lutz D, et al. Pretransplant risk assessment in renal allograft recipients using virtual crossmatching. Am J Transplantation 2007; 626.
19. Tyan DB, Li Va, Czer L, et al. Intravenous immunoglobulin suppression of HLA antibody in highly sensitized transplant candidates and transplantation with a histoincompatible organ. Transplantation 1994; 57: 553.
20. Claas FJH, Van Leewen A, Van Rood J. Hyperimmunized patients do not need to wait for an HLA identical donor. Tissue Antigens 1999; 34: 23.
21. Policy 3.5.11.3. Allocation of Deceased kidneys: Sensitized wait list candidates - calculated PRA (CPRA). Policies of the OPTN UNOS. Available at: www.unos.org/PoliciesandBylaws2/policies. Accessed July 6, 2007.
22. Appel JZ III, Hartwig MG, Cantu E III, et al. Role of flow cytometry to define unacceptable HLA antigens in lung transplant recipients with HLA-specific antibodies. Transplantation 2006; 81: 1049.
23. Zangwill SD, Ellis TM, Zlotocha J, et al. The virtual crossmatch - A screening tool for sensitized pediatric heart transplant recipients. Pediatr Transplant 2006; 10: 38.
24. Warren DS, Zachary AA, Sonnenday CJ, et al. Successful renal transplantation across simultaneous ABO incompatible and positive cross-match barriers. Am J Transpl 2004; 4: 561.
25. Zachary A, Montgomery R, Ratner L, et al. Specific and durable elimination of antibody to donor HLA antigens in renal transplant patients. Transplantation 2003; 76: 1519.